ProBio

Global Biologics and CGT Symposium 2023- South Korea

Date: 19^th May 9:00-18:00 (GMT+9)

Address: Gravity Seoul Pangyo

ProBio is pleased to invite you to the Global Biologics and CGT Symposium 2023 - South Korea on May 19^th. Our goal is to strengthen communication within the Korean bio-industry, shorten timelines, and provide valuable insight into the decision points of the drug development process. This one-day event will cover the entire spectrum of biologics and cell & gene therapy.

At the symposium, you'll have the opportunity to meet with industry professionals in person and gain in-depth insights into every stage of the drug development process - from discovery to commercialization, from process to regulation, and from challenge to solution.

Time	Topic
9:30-9:40	Opening Brian Hosung Min, CEO, ProBio
Session 1: Cell and Gene Therapy CDMO
9:40-10:10	Accelerating CGT with robust and customized plasmid platform Ming Ni, Principal Project Manager, ProBio 1. Plasmid for LVV 2. Plasmid for AAV 3. Plasmid for mRNA vaccine/drug 4. Plasmid for DNA vaccine/drug
10:10-10:50	Integrated one-stop solution for mRNA CMC Xiao Pan, Director of Platform R&D Dept., ProBio 1. Introduction to ProBio integrated mRNA solution 2. mRNA CMC challenges and strategies 3. Platforms for IVT mRNA and LNP systems 4. Analytics and quality control considerations
10:50-11:10	Break
11:10-11:30	Reserved for invited speaker Hyeong Cheol Kim, CTO, Curocell Inc.
11:30-12:00	Advanced one-stop gene therapy solutions Ming Ni, Principal Project Manager, ProBio 1. Proprietary AAV packaging cell line: PowerS^TM-293 2. Scalable AAV manufacturing processs
12:00-13:00	Lunch
13:00-13:30	Points to consider in the CMC study for IND application of biologics and cell and gene therapy drugs (online) Sean Liour, VP of PM & RA Dept., ProBio 1. Introduction of the role of CMC study in the IND application. 2. The coverage of manufacturing process, product specification, analytical methods, and stability study at IND stage. 3. The control of adventitious agents 4. Potential differences of the CMC regulatory review practices between FDA and NMPA
Session 2: Biologics Discovery
13:30-14:00	Application of naïve Fab & VHH library in TAA antibody discovery for CAR-T & T-cell engager bi-specific antibody Li Chen, Director of Biologics Discovery Dept., ProBio 1. Brief overview of tumor-associated antigen (TAA) and its therapeutic modality. 2. Solution of TAA antibody discovery using naïve library 3. Case study: anti-ROR1 VHH antibody in CAR-T & T-cell engager bsAb
14:00-14:30	Accelerated ADC development via integrated antibody discovery platform Li Chen, Director of Biologics Discovery Dept., ProBio 1. Brief overview of history and current trending of antibody-drug conjugates. 2. Tools and strategies for naked antibody discovery for ADCs 3. Early-stage pharmacology evaluation of naked antibody for ADC application 4. Pharmacology assessment of ADC candidates
14:30-14:50	Break
Session 3: Biologics CDMO
14:50-15:20	Reserved for invited speaker Sang Jeon Chung, CEO, AbTis
15:20-16:20	Overcome challenges in process development of bispecific antibody & recombinant proteins Ying Li, Purification Process Development Director, ProBio 1. Introduction of ProBio Toolbox Platform 2. CMC challenges for bispecific antibody and recombinant protein 3. Toolbox solutions for cell line/cell culture/purification/formulation process development 4. ProBio PAD capability updates
16:20-16:30	Closing Jihwan Rhee, Regional Commercial BD Head of AP1, ProBio

Note: There will be a confirmation email once the registration is accepted

If you have any questions about it, please kindly contact us through email: [email protected]